# US 2025/0375487 A1 · Use of a microbiota-modulating agent for enhancing bone development and/or bone strength

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375487 A1
- Document ID: US20250375487A1
- Status: Published application
- Kind: A1
- Application number: 18/877,530
- Filed: 2023-06-19
- Published: 2025-12-11
- Earliest claimed: 2022-06-22
- Assignees: Societe des Produits Nestle S.A.
- Applicants: Societe Des Produits Nestle S.A.
- Inventors: MARIE NOELLE HORCAJADA; NICOLAS BONNET
- Web page: https://patentgrep.com/patent/US20250375487A1

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/10: for osteoporosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to the use of a microbiota-modulating agent for enhancing bone development and/or bone strength. wherein the microbiota-modulating agent modulates the abundance of one or more bacterial taxa selected from Intestinimonas butyriciproducens, Turicibacter sanguinis, Paraprevotella clara, and Acidaminococcaceae in the gut of the subject.

## Claims

### Claim 1

A method for enhancing bone development and/or bone strength in a subject in need thereof, wherein the microbiota-modulating agent modulates the abundance of one or more bacterial taxa selected from Intestinimonas butyriciproducens, Turicibacter sanguinis, Paraprevotella clara, and Acidaminococcaceae in the gut of the subject comprising administering to the subject a microbiota-modulating agent.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent is Intestinimonas butyriciproducens and Turicibacter sanguinis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent is an oligosaccharide mixture comprising at least one sialylated oligosaccharide, at least one fucosylated oligosaccharide, and at least one N-acetylated oligosaccharide.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent is a combination comprising an oligosaccharide mixture and Intestinimonas butyriciproducens and/or Turicibacter sanguinis, wherein said oligosaccharide mixture comprises at least one sialylated oligosaccharide, at least one fucosylated oligosaccharide and/or at least one N-acetylated oligosaccharide, and wherein the oligosaccharide mixture and Intestinimonas butyriciproducens and/or Turicibacter sanguinis are administered separately, simultaneously or sequentially.

### Claim 5 (depends on 3)

The method according to claim 3, wherein:
(a) the at least one sialylated oligosaccharide is selected from the group consisting of 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL), syalyllacto-N-tetraose b (LSTb), syalyllacto-N-tetraose c (LSTc), disyallacto-N-tetraose, and combinations thereof, preferably wherein the at least one sialylated oligosaccharide is selected from 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL) and combinations thereof;
(b) the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose (2′FL), 3-fucosyllactose (3FL), difucosyllactose (diFL), lacto-N-fucopentaose-I (LNFP-I), lacto-N-fucopentaose-II (LNFP-II), lacto-N-fucopentaose-III (LNFP-III), lacto-N-fucopentaose-V (LNFP-V), lacto-neofucopentaose V (LNnFP-V), lacto-N-difucosylhexaose-I (LNDFH-1), lacto-N-neodifucosylhexaose (LNnDFH), monofucosyllacto-n-hexaose-III (MFNLH-III), difucosyllacto-N-hexaose-a (DFLNHa) and combinations thereof, preferably wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose (2′FL), difucosyllactose (diFL), and combinations thereof; and/or
(c) the at least one N-acetylated oligosaccharide is selected from the group consisting of N-acetyl-glucosamine, N-acetyl-galactosamines, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, preferably wherein said at least one N-acetylated oligosaccharide is selected from lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and combinations thereof.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the oligosaccharide mixture comprises: (a) sialyllactose (3′-SL) and 6′-sialyllactose (6′-SL); (b) 2′-fucosyllactose (2′FL) and difucosyllactose (diFL); and (c) lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).

### Claim 7 (depends on 3)

The method according to claim 3, wherein the oligosaccharide mixture comprises:
(a) 10 to 35 wt %, with respect to the total weight of the oligosaccharide mixture, of at least one sialylated oligosaccharide;
(b) 30 to 80 wt %, with respect to the total weight of the oligosaccharide mixture, of at least one fucosylated oligosaccharide; and (c) 10 to 35 wt %, with respect to the total weight of the oligosaccharide mixture, of at least one N-acetylated oligosaccharide.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent is in a form selected from the group consisting of a nutritional composition, a medical food product for clinical nutrition, or a supplement.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent is in the form of an infant formula.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the composition comprises:
(a) 0.01 to 2 wt %, of at least one sialylated oligosaccharide, with respect to the total weight of the composition in powder form;
(b) 0.05 to 3 wt %, of at least one fucosylated oligosaccharide, with respect to the total weight of the composition in powder form; and
(c) 0.01 to 1 wt %, of at least one N-acetylated oligosaccharide, with respect to the total weight of the composition in powder form.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the subject is a human.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the subject is selected from the group consisting of a child, a toddler, and an infant.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent increases the abundance of Intestinimonas butyriciproducens and/or Turicibacter sanguinis in the gut of the subject.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the microbiota-modulating agent increases one or more bone parameter selected from the group consisting of bone mineral density (BMD), trabecular bone volume fraction (BV/TV), cortical bone volume (Ct.BV) and bone ultimate force (FMax).

### Claim 15

A microbiota-modulating agent comprising Intestinimonas butyriciproducens and Turicibacter sanguinis.
